Miami, Florida (PRWEB) September 16, 2011
Nutri-Med Logic Corp: Benefits of a soy nutrient "Poly-Enyl-Phosphatidylcholine (PPC)" in both liver and intestinal health, as it would relate to Metabolic Abnormalities.
A recently published study suggests that activation of certain liver receptors, called FX Receptors, improved Metabolic Abnormality, by suppressing the production of triglycerides in the liver. Poly-Enyl-Phosphatidylcholine (PPC) is a nutrient extracted from soy, which has been recommended for liver health in Europe for about half century. Poly-Enyl-Phosphatidylcholine is, also, very important to the intestinal homeostasis, highly relevant to FX Receptors.
The FX Receptors play a key role in the regulation of an enzyme (CYP7A1), used in the production of bile acid (digestion of fat in the intestine) from cholesterol. Dysregulation of this enzyme (CYP7A1) has been implicated in Functional Cholestasis (reduced bile flow) and the formation of Cholesterol Gallstones. (1)
In another word, inactivation of FX Receptors has caused a reduction in bile flow (functional cholestasis) and increased the production of triglycerides and the amount of existing cholesterol (hyperlipidemia and hypercholesterolemia), whereas the activation of FX Receptors has reduced the triglycerides production in the liver and has increased the excretion of cholesterol. (2)
The activation or inactivation of the FX Receptors, in great part, is dependent on status of the intestinal flora, or in another word in the status of the good bacteria colony in the intestine. (3)
The intestinal flora’s activation or inactivation of FX Receptors, in turn, is mainly a function of two elements called NAD and NADH, which all of the body’s cells use for a process called Redox (oxidation/reduction).
Interestingly the same process is applicable to the intestinal colony of good bacteria, whereas the higher concentration of NADH (highly reduced environment) inactivates FX Receptors and vice versa. (4, 5)
It is suggested that a way to reduce the NADH would be through dietary intake of Electrophilic Methyl Groups, which have the ability to remove a hydrogen (H), mainly from NADH, converting it to NAD.
Lowering the concentration of NADH has stimulated the FX receptors, which translates to lowering the production of hepatic (liver) triglycerides and increasing the excretion of Cholesterol / improvement of bile flow. One nutrient that belongs to Electrophilic Methyl Group is Poly-Enyl-Phosphatidylcholine. (6)
Poly-Enyl-Phosphatidylcholine (PPC) is also referred to as Essential Phospholipid "EPL" due to its high degree of Essential Polyunsaturated Fatty Acids and, for about half of century, dietary supplementation of this nutrient has been recommended, in Europe, for the liver health of those with fatty and/or alcoholic liver.
Studies have also suggested that a part of phosphatidylcholine (lyso-phosphatidylcholine) incorporates into the intestinal mucosa and could improve the healthy functioning of the mucous membranes of the intestinal tract, as well. (7, 8)
In conclusion, Nutri-Med Logic Corp agrees with the study published in American Journal of Physiology but adds that since the activation / inactivation of the FX Receptors are also dependent on the homeostasis of the intestinal flora, the Redox Status of the intestinal flora should have received equal importance.
Nutri-Med Logic Corp is a producer of dietary supplements, including Poly-Enyl-Phosphatidylcholine 425mg, an important dietary supplement of liver and intestinal health.
Nutri-Med Logic's products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and, also, packaged in pharmaceutical facilities.
It must be noted that the studies, sources or statements, above and below, have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of dietary supplementation of Poly-Enyl-Phosphatidylcholine; nor equate its supplementation to prevention, treatment or cure.
(1) Gallstones: pathogenesis. Lancet 338 (8775): 1117–21.
(2) Physiology, Vol. 23, No. 5, 286-295, October 2008
(3) Physiological Reviews. Jan. 2009 vol. 89, no. 1, pp. 147-191.
(4) The American Journal of Clinical Nutrition 43: JAN. 1986, pp 98-107.
(5) Journal of Lipid Research, 1983, Vol. 24.
(6) British Journal of Nutrition (2001), 85, 409-414.
(7) Journal of Nutritional Biochemistry, Vol. 4, Issue 12, Dec. 1993,pp 690-694.
(8) American Journal of Clinical Nutrition, 43: JANUARY 1986, pp 98-107.